Although the interplay between DCs and CD8+ T-cells within TDLNs is essential for anti-tumor immunity and appears critical for the response to ICI therapy, prior research has predominantly focused on tumor immunity within the primary tumor site and peripheral blood [29]. The gene discussed is CD8A; the disease is neoplasm.